Primary Immune Thrombocytopenia clinical trials

Explore recruiting primary immune thrombocytopenia clinical trials.

Recruiting primary immune thrombocytopenia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Immune Thrombocytopenia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia

Poland, Spain, Bulgaria, Italy, Netherlands, Croatia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

Italy, Czechia, Poland, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA

Poland, Czechia, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults with Chronic Primary Immune Thrombocytopenia

Bulgaria, Spain, Netherlands, Italy, Poland, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

Norway, Spain, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects with Immune Thrombocytopenia (ITP)

Spain, Greece, Bulgaria

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Primary Immune Thrombocytopenia trials by city

Primary Immune Thrombocytopenia in Toronto Primary Immune Thrombocytopenia in Vancouver Primary Immune Thrombocytopenia in Montreal Primary Immune Thrombocytopenia in Calgary Primary Immune Thrombocytopenia in Edmonton Primary Immune Thrombocytopenia in Ottawa Primary Immune Thrombocytopenia in Winnipeg Primary Immune Thrombocytopenia in Quebec City Primary Immune Thrombocytopenia in Hamilton Primary Immune Thrombocytopenia in Kitchener Primary Immune Thrombocytopenia in London Primary Immune Thrombocytopenia in Halifax Primary Immune Thrombocytopenia in New York Primary Immune Thrombocytopenia in Los Angeles Primary Immune Thrombocytopenia in Chicago Primary Immune Thrombocytopenia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease